Clinical Trial Update: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a triple-targeted CD19/CD20/CD22 cell therapy for relapsed/refractory B-cell lymphoma was terminated. The study status is TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Triple-targeted CD19/CD20/CD22 cell therapy

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 | Status: TERMINATED